BRIEF published on 08/07/2024 at 13:05, 2 years 2 months ago Evotec SE to Announce First Half-Year 2024 Results on 14 August 2024 Financial Results Conference Call Evotec SE Webcast First Half-year 2024
PRESS RELEASE published on 08/07/2024 at 13:00, 2 years 2 months ago Evotec SE reports first half-year 2024 results on 14 August 2024 Evotec SE to report first half-year 2024 results on 14 August 2024. Conference call scheduled to discuss financial performance and updates. Webcast available on www.evotec.com/en/investor-relations/financial-publications Conference Call Financial Performance Evotec SE Webcast First Half-year Results
BRIEF published on 08/06/2024 at 21:12, 2 years 2 months ago Evotec Provides Updated Fiscal Guidance for 2024 Adjusted EBITDA Revenue Forecast Sustainable Growth 2024 Guidance Evotec
BRIEF published on 08/06/2024 at 21:09, 2 years 2 months ago Evotec SE Updates Financial Guidance for 2024 Adjusted EBITDA Revenue Forecast Financial Guidance Evotec SE R&D Expenditure
PRESS RELEASE published on 08/06/2024 at 21:07, 2 years 2 months ago Evotec provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting moderate revenue growth, reduced R&D expenditures, and adjusted EBITDA; aims for sustainable profitable growth amid market challenges Adjusted EBITDA Revenue Growth Evotec SE Guidance Update R&D Expenditures
PRESS RELEASE published on 08/06/2024 at 21:04, 2 years 2 months ago EQS-Adhoc: Evotec SE provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting revenue and EBITDA adjustments due to slower sales conversion and margin pressures, focusing on sustainable growth EBITDA Revenue Evotec SE Sustainable Growth Guidance Update
BRIEF published on 07/10/2024 at 07:35, 2 years 3 months ago Evotec and Pfizer Collaborate to Advance Drug Discovery in France Drug Discovery Metabolic Diseases Evotec Pfizer Infectious Diseases
PRESS RELEASE published on 07/10/2024 at 07:30, 2 years 3 months ago Evotec and Pfizer collaborate to advance drug discovery in France Evotec SE collaborates with Pfizer to focus on early discovery research for metabolic and infectious diseases in France. The multi-year agreement includes research support and potential milestones Drug Discovery Evotec SE France Pfizer Metabolic And Infectious Diseases
BRIEF published on 07/08/2024 at 14:05, 2 years 3 months ago Just – Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz Partnership Biosimilars Evotec Sandoz Biologics
PRESS RELEASE published on 07/08/2024 at 14:00, 2 years 3 months ago Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz Evotec SE's biologics segment, Just - Evotec Biologics, expands partnership for biosimilars with Sandoz, securing long-term commercial supply. Collaboration aims for cost-efficient development Evotec SE Biosimilars Just - Evotec Biologics Sandoz Commercial Supply
Published on 10/30/2026 at 23:35, 1 day 17 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 17 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 22 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 1 hour ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 6 hours 30 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 12 hours 5 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 18 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 18 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 5 hours ago Capital increase through exercise of subscription rights
